NCT05096481: An ongoing trial by Nationwide Children's Hospital
This trial is ongoing. It must report results 4 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05096481 |
|---|---|
| Title | Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 18, 2024 |
| Completion date | June 15, 2028 |
| Required reporting date | June 15, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |